
|Videos|September 22, 2022
Next Generation of CAR-T Therapies in Lymphoma
Experts comment on the future of CAR T-cell therapy development and the use of dual CAR-T and CAR-T retreatment.
Advertisement
Episodes in this series

Advertisement
Related to this article

Qingqing Cai, MD, PhD, discussed early efficacy data for rocbrutinib plus R-CHOP in untreated non-GCB DLBCL and how they compare with frontMIND at ESMO 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer
2
Lung Cancer Survival Rate Climbs to 31%, Although Screening Gaps Persist
3
Galinpepimut-S Improves Overall Survival in Phase 3 AML Maintenance Trial
4
FDA Grants Final Approval to Generic Binimetinib in BRAF-Mutant Melanoma, NSCLC
5



